The latest announcement is out from Kamada ( (IL:KMDA) ).
Kamada Ltd. announced the opening of a new plasma collection center in San Antonio, Texas, on March 19, 2025. This expansion is part of Kamada’s growth strategy, increasing its collection capacity for specialty plasma, such as Anti-Rabies and Anti-D, to meet the rising demand for hyper-immune plasma and reduce raw material costs. The new center, operated by Kamada Plasma, is expected to contribute $8 million to $10 million annually in revenue from normal source plasma sales at full capacity. Kamada plans to submit approval applications for the site to the U.S. FDA and the European Medicines Agency in the second half of 2025, with anticipated decisions within 9-12 months.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in plasma-derived therapies for rare and serious conditions. The company focuses on organic growth through commercial activities, business development, and expanding plasma collection operations. Kamada’s portfolio includes FDA-approved specialty plasma-derived products and equine-based anti-snake venom products, with a significant presence in the U.S. and Israel.
YTD Price Performance: 12.50%
Average Trading Volume: 222,219
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $380.3M
See more data about KMDA stock on TipRanks’ Stock Analysis page.